A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

Abstract

BACKGROUND Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed. METHODOLOGY/PRINCIPAL FINDINGS Thirty-six patients treatment-naïve advanced melanoma patients received sorafenib 400 mg p.o. twice daily… (More)
DOI: 10.1371/journal.pone.0015588

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Ott2010API, title={A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates}, author={Patrick Ott and Anne Regitze Hartmann Hamilton and Christina Liew Shu Min and Sara Safarzadeh-Amiri and Lauren Goldberg and Joanne Yoon and Herman Terence Yee and Michael Buckley and Paul J. Christos and John J. Wright and David Polsky and Iman Osman and Leonard Liebes and Anna C. Pavlick}, booktitle={PloS one}, year={2010} }